Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
'Billionaires own my mouldy rental property'
More than half a million rented homes - both private and social - have black mould issues in England, a 2023 government survey found. In Rotherham, we met an elderly couple who have lived in the same ...
Chronicle15h
From Friendship to Forever at Duke
For four years, Justin Frye and Jason Funaro were good friends. Frye, a Physician Assistant in Infectious Diseases since 2016 ...
ITV Loose Women's Andrea McLean rushed to hospital after dismissing flu-like symptoms
Andrea McLean, 55, was left 'terrified' by her time in hospital, and collapsed on her bathroom floor, lying for an hour ...
News Medical on MSN1h
GUK1 enzyme plays crucial role in lung cancer metabolism and growth
Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.
FierceBiotech12h
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Peninsula biotech sheds 60% of its value as it pauses key clinical trial
A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...